SNYR (synergychc.com) Future Price to Earnings
Synergy CHC Corp owns a portfolio of wellness brands with resilient demand, ensuring long-term asset utilization. The company's forward P/E ratio illustrates investor confidence trends, with the metric currently at 0.60. The holding company accumulates profitable beauty brands, creating a stable cash cow. Efficiency is maintained through a lean management team and the full outsourcing of operational processes.
Summary analytical data breakdowns for Synergy CHC Corporation (SNYR)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- debt level and financial liquidity data:
Total Debt to Capital Synergy CHC Corp|SNYR - Long-Term Liabilities to Capital|Short-Term Debt to Equity Synergy CHC Corp|SNYR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Synergy CHC Corp|SNYR - Long-Term Debt Volume|Company Current Liabilities Synergy CHC|Quick Liquidity synergychc.com
- financial results and valuation multiples details:
SNYR - Company Profit|Projected Future Earnings Synergy CHC Corp|SNYR - Market Cap to Earnings|Future Price to Earnings Synergy CHC Corp|SNYR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Synergy CHC Corp|SNYR - Operating profit before depreciation charges|Net earnings per share for the last 12 months Synergy CHC|SNYR - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months synergychc.com|SNYR - Earnings per share increase in current year
Fundamental valuation:SNYR Synergy CHC
The forward P/E reflects the ratio of the current market value of Synergy CHC Corp (SNYR) to its projected net income, allowing for an assessment of the cost of each dollar of expected earnings. This expected price-to-earnings multiple for the company separates speculative noise from fundamental value by accounting for the efficiency of the issuer's contract manufacturing and logistics hubs, helping investors determine the degree of undervaluation or the risk of overpaying for the asset.
Main competitors
Projected Price to Earnings HLN (Haleon)|KVUE (Kenvue Inc) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma Corp VRNA|Jyong Bio (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|amneal.com - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech S.A. - Future Price to Earnings Multiple|LQDA (Liquidia Technologies) - Forward P/E Multiple|Projected Price to Earnings Ratio Galapagos Corp GLPG|Future Price to Earnings ANI Pharmaceuticals (ANIP)|MNKD (mannkindcorp.com) - Future Price to Earnings Multiple|Future Price to Earnings Amphastar Pharmaceuticals, Inc. AMPH|Market Cap to Projected Earnings Pacira Pharmaceuticals (PCRX)|SPRY: Projected Price to Earnings|Projected Price to Earnings Ratio Theravance Corp|Aquestive Therapeutics (AQST) - Future Price to Earnings|Price to Future Earnings Ratio SCPH|TECX (Tectonic Therapeutic Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio Tonix Pharma TNXP|Future Price to Earnings China SXT Pharmaceuticals (SXTC)|EPRX (eupraxiapharma.com) - Future Price to Earnings Multiple|Forward P/E Multiple BHST (BioHarvest Sciences)|Forward Price to Earnings Multiple invizyne.com|ORMP: Projected Price to Earnings|Projected Price to Earnings Ratio Entera Bio Ltd.|HYFT (MindWalk) - Projected Price to Earnings|ABVC BioPharma, Inc - Future Price to Earnings Multiple|CPIX (Cumberland Pharmaceuticals) - Forward P/E Multiple|Projected Price to Earnings quantumbiopharma.com (QNTM)|Forward P/E Multiple FGEN|TELO (Telomir Pharmaceuticals Inc) - Future Price to Earnings Multiple|Forward P/E Multiple RANI (Rani Therapeutics Holdings, Inc.)|RLYB - Projected Price to Earnings|LEXX: Projected Price to Earnings|Future Price to Earnings Multiple PULM (pulmatrix.com)|PTHL: Forward P/E Multiple|Projected Price to Earnings Aptorum Group|Future Price to Earnings Lyra Therapeutics, Inc|Projected Price to Earnings Ratio Impact BioMedical, Inc. IBO|Future Price to Earnings TNF Pharmaceuticals (TNFA)|YCBD (cbdmd.com) - Future Price to Earnings Multiple|Future Price to Earnings PainReform PRFX|CYTO (Altamira Therapeutics Ltd) - Price to Expected Earnings Ratio|LIPO - Future Price to Earnings|Market Cap to Projected Earnings OptiNose Corp OPTN|Pieris Pharmaceuticals (PIRS) - Future Price to Earnings|Price to Future Earnings Ratio PROC|Projected Price to Earnings PTPI|Projected Price to Earnings Ratio Qilian International Holding Group QLI|Future Price to Earnings ACELYRIN, Inc. (SLRN)|TFFP (TFF Pharmaceuticals, Inc) - Future Price to Earnings Multiple
